Alliance for Pandemic Preparedness

November 16, 2020

Safety and Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial

Category:

Topic:

Keywords (Tags):

A phase 2 randomized, double-blind, placebo-controlled trial of inhaled nebulized interferon beta-1a (SNG001) for patients hospitalized with COVID-19 (n=101) found that patients who received the study drug had greater odds of improvement on the WHO ordinal scale for clinical improvement (OSCI) (OR = 2.32) on day 15 or 16 and were more likely to recover to an OSCI score of 1 (no limitation of activities) during treatment (HR = 2.19) compared to placebo. 66 (67%) patients required supplemental oxygen at enrollment (29 in the placebo group and 37 in the study drug group).  Headaches were the most frequently reported adverse event (15% vs. 10% in the study drug and placebo groups, respectively). Three deaths occurred in the placebo group and none in the study drug group.

Monk et al. (Nov 2020). Safety and Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(20)30511-7